| | New outcomes study for ticagrelor (BRILINTA™) to examine longer-term treatment for post- ACS patients | | | AstraZeneca today announced the initiation of a large, international, clinical outcomes study for the investigational oral antiplatelet, ticagrelor (BRILINTA™/BRILIQUE™) in collaboration with the Brigham and Women’s Hospital-based Thrombolysis in Myocardial Infarction (TIMI) Study Group. The PEGASUS-TIMI 54 study is scheduled to begin patient enrolment during the fourth quarter 2010. | |  View full press release | | | This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. | | | |
No comments:
Post a Comment